evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

85 questions · 85 findings · 16 reviews · Airways

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 4 · 4.7%GRADE not reported 4 · 4.7%Very low 4 · 4.7%Low 13 · 15.3%Moderate 42 · 49.4%High 18 · 21.2%

Intervention not reported

Moderate to severe exacerbations ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 5452(6 RCTs)

The intervention showed no clear difference in moderate to severe exacerbations ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of… (high certainty).

1 finding from 1 review

Medical or surgical intervention, or both, for gastro‐oesophageal reflux disease vs nil intervention, delayed intervention control, or placebo

Exacerbations: number of people experiencing moderate or severe exacerbations · treatment for asthma in adults and children with asthma and GORD

Medical or surgical intervention, or both, for gastro‐oesophageal… showed no clear difference in number of participants with moderate/severe acute exacerbations… compared with nil intervention, delayed intervention control, or placebo (low certainty).

1 finding from 1 review

Multi‐component interventions (with telehealth as a component of care) vs usual care

Number of people experiencing at least 1 exacerbation/moderate to severe exacerbation · patients with chronic obstructive pulmonary disease

It is very uncertain whether multi‐component interventions (with telehealth as a component of care) changes number of people experiencing at least 1 exacerbation/moderate to… compared with usual care (very low certainty).

1 finding from 1 review

Multi‐component intervention vs control

Exacerbations: number of people experiencing moderate or severe exacerbations · COPD

It is very uncertain whether multi‐component intervention changes exacerbations: number of people experiencing moderate or severe… compared with control (very low certainty).

1 finding from 1 review

Mepolizumab 100 mg vs placebo

Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg leads to lower rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab 300 mg vs placebo

Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 300 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (moderate certainty).

1 finding from 1 review

Mepolizumab 300 mg vs placebo

Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 300 mg probably leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (moderate certainty).

1 finding from 1 review

Mepolizumab 100 mg vs placebo

Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations All participants compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 10 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).

1 finding from 1 review